Trump administration considers outcomes-based approach to lower drug prices; Sanofi to acquire vaccines biotech; Nestle partners with Enterome to develop microbiome-based diagnostics
Adamis receives FDA approval for EpiPen rival Symjepi; Clovis reports positive trial results for ovarian cancer drug Rubraca; hedge fund billionaire John Paulson joins Valeant board of directors
50% of consumers say they will share their health data with tech giants; pharma CEOs expect pricing proposal from Trump administration; FDA approves generic versions of Strattera
In short, he'll be further along the learning curve than anyone ever tapped for the nation's number-one public health regulatory slot.
Trump reiterates call to bring down drug prices; Novartis renews its focus on immunotherapies; a new bill would allow drugs to be imported
Despite budgets bouncing back from a decrease in 2015, big threats have appeared that may temper future plans, Iskowitz writes.
In short, the Trump team, I predict, will seek to tweak FDA.
Finally, a Congress and president who see pharma as a resource and not a villain, Flaum writes.
Pharma execs raise concerns about Trump's plans for the FDA; Merck ends study of experimental Alzheimer's drug; Amgen seeks new indication for Blincyto
Last week President Trump told drugmakers that 'the pricing has been astronomical.'
It's hard to be against the concept of reform, but Trump is better known for epithets than policy details, Kamp writes.
A Haymarket Media survey of more than 700 client-side marcomms execs in the US reveals the shift in power will not significantly affect budgets.
A new survey found that 34% of healthcare and pharma marketers say that the election of President Trump will not affect their marketing budgets.